Nicolas Villain, M.D., Ph.D.

Sorbonne University - APHP - Pitié-Salpêtrière Hospital

Contact Information

Nicolas Villain, M.D., Ph.D.
Paris, France

Professional Information

Dr.
Sorbonne University - APHP - Pitié-Salpêtrière Hospital
https://twitter.com/nvillain_alz

Education

- Fellowship in Behavioral & Cognitive Neurology, Department of Neurology, Pitié-Salpêtrière Hospital, Paris, France: 2017-2021 - Board Certification in Neurology, 2017 - MD, 2017 - Resident in Neurology, Assistance Publique – Hôpitaux de Paris (AP-HP) : 2012-2017 - PhD in Neuroscience, 2009 - MSc Cellular Biology and Neuroscience, 2006 - Inserm-Liliane Bettencourt MD-PhD Program, 2004 - Medical School, University of Caen Normandy: 2002-2005 & 2009-2012

Financial Disclosure

Member reports the following financial or other potential conflicts of interest:
[Last updated: Oct 11, 2022]

NV received research support from Fondation Bettencourt-Schueller, Fondation Servier, Union Nationale pour les Intérêts de la Médecine (UNIM), Fondation Claude Pompidou, Fondation Alzheimer and Fondation pour la Recherche sur l’Alzheimer; travel grant from the Movement Disorders Society, Merz-Pharma, UCB Pharma, and GE Healthcare SAS; is an unpaid principal investigator or sub-investigator in NCT04241068 (aducanumab, Biogen), NCT04437511 (donanemab, Eli-Lilly), NCT05463731 (remternetug, Eli-Lilly), NCT04592341 (gantenerumab, Roche), NCT03887455 (lecanemab, Eisai), NCT03352557 (gosuranemab, Biogen), NCT03828747 and NCT03289143 (semorinemab, Roche), NCT04619420 (JNJ-63733657, Janssen – Johnson & Johnson), NCT04374136 (AL001, Alector), NCT04592874 (AL002, Alector), NCT04867616 (bepranemab, UCB Pharma), NCT04777396 and NCT04777409 (semaglutide, Novo Nordisk); and has given unpaid lectures in symposia organized by Eisai and the Servier Foundation.